Cibus (CBUS) Reports Q3 2026 Results with Improved Net Loss and Strategic Shift to Direct-Sales Model
Cibus, Inc. (CBUS) reported third-quarter 2026 financial results characterized by a narrowing net loss of $21.9 million, an improvement from the $24.3 million lost in the prior year period. While quarterly revenue remained modest at $0.8 million—primarily driven by collaboration agreements—the company saw a 35% year-over-year increase in nine-month revenue to $3.5 million due to new research funding and its sustainable ingredients program. The company is undergoing a strategic pivot toward a direct-sales model for its biofragrance business, which management estimates could reach $100 million in peak annual revenue with high gross margins. To preserve liquidity, Cibus has implemented significant cost-saving measures, including laboratory consolidation and workforce reductions, reducing total operating expenses to $13.3 million. However, the company noted it expects to need additional capital in the near term as its current cash runway extends only into early Q1 2027.
Tickers: $CBUS
Topics: cash runway net loss operating expenses revenue sustainable ingredients
Read the full article at Motley Fool
Part of the story Cibus (CBUS) Reports Q3 2026 Results with Improved Net Loss and Strategic Shift to Direct-Sales Model (5 articles)